Scripscan:Glenmark Pharmaceuticals Ltd
cmp:318
Code:532296
Story:Glenmark Pharmaceuticals reported strong sales growth for the quarter which was higher than street estimates driven by US, India and RoW formulation segments.The company continues to witness strong traction in US business on back of improving market share in existing products and new product launches. However, margins were under pressure on back of increase in raw-material prices and unfavorable product mix (higher RoW segment sales).The company expects recurring EBITDA margins to be in range of 21-22% for FY12.Glenmark also launched generic Malarone in September and has 180-days exclusivity. The company also witnessed solid growth in India which was up by 19.7% YoY while RoW market for Glenmark grew by 82.4% YoY on back of Russia/CIS and Africa region. Glenmark reported EBITDA margins (ex R&D income and Forex loss) of 20.5%, below estimates of 21.8% on back of increasing raw-material cost. The raw-material cost increased by 34.2% YoY on back of change in product mix, increase in raw-material prices and higher sample cost. As a result the gross margins contracted by 124bps.The employee cost was up by 18.3% YoY, while SG&A cost (ex forex loss) increased by 27.9% YoY. Further the company’s net profit was marred by one time payment of USD29mn to Paul Capital and MTM forex loss of Rs 850mn.Remains a hold at present levels.
Wednesday, December 21, 2011
Plethico Pharmaceuticals Ltd:-Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger
Scripscan:Plethico Pharmaceuticals Ltd
cmp:368
Code:532739
Story:Plethico Pharmaceuticals manufactures nutraceuticals and over-the-counter pharmaceuticals products. The company''s USbased subsidiary Natrol has a strong portfolio of brands in the healthcare and wellness segment. It caters to the US and other export markets such as CIS, Africa, Latin American countries, Gulf Co-operation Council (GCC) and South East Asian countries. In recent quarters, the company has not performed well in South East Asia, the Middle East and Eastern European markets. The company''s performance has been quite erratic since the last several quarters giving little visibility to investors on what to expect. It has a negative cash flow and debt in excess of Rs 580 crore. A substantial portion of its cash flow is utilised for capital expenditure, working capital, or repayment of debt. The consumer sentiment in the US and other parts of the world has been weak due to the ongoing uncertainty in the financial markets.This doesn''t augur well for the company.Remains a hold though at present levels.
cmp:368
Code:532739
Story:Plethico Pharmaceuticals manufactures nutraceuticals and over-the-counter pharmaceuticals products. The company''s USbased subsidiary Natrol has a strong portfolio of brands in the healthcare and wellness segment. It caters to the US and other export markets such as CIS, Africa, Latin American countries, Gulf Co-operation Council (GCC) and South East Asian countries. In recent quarters, the company has not performed well in South East Asia, the Middle East and Eastern European markets. The company''s performance has been quite erratic since the last several quarters giving little visibility to investors on what to expect. It has a negative cash flow and debt in excess of Rs 580 crore. A substantial portion of its cash flow is utilised for capital expenditure, working capital, or repayment of debt. The consumer sentiment in the US and other parts of the world has been weak due to the ongoing uncertainty in the financial markets.This doesn''t augur well for the company.Remains a hold though at present levels.
Natco Pharma Ltd:-Buy/sell/growth prospects and recommendation,news and results,target and analysis,view and outlook,multibagger
Scripscan:Natco Pharma Ltd
cmp:225
Code:524816
Story:The Hyderabad-based pharmaceutical company is engaged in the manufacture of active pharmaceutical ingredients and formulations with a focus on oncology. The company owns a retail pharmacy store chain in the US and a small distribution business in Brazil. It is also engaged in contract manufacturing. As part of its marketing strategy, Natco has tied up with leading companies such as Mylan, Dr Reddy''s Labs, Actavis, Breckinridge and Lupin.Net sales and net profit have grown at a CAGR of 20.6% and 17.5%, respectively, in the last five fiscals. The company has been paying dividends since the last five years at an average payout of 10.5%. It plans to spend nearly 5% of its revenues on R&D. The company recently raised Rs 67.5 crore through a qualified institutional placement to fund its expansion plans and meet its working capital requirements. A couple of private equity players have picked up a small stake in the company. Dilip Shanghvi, the promoter of Sun Pharma, has bought a 3.2% stake.Natco Pharma''s stock which had depreciated by 40% in the last 12 months to November, has gained by 20% after the stake deals. With a market capitalisation of Rs 692 crore, the company is valued at one-and-a-half times its consolidated revenues during the last four trailing quarters. These are fair valuations given that the stock is a long-term play for the investors.
cmp:225
Code:524816
Story:The Hyderabad-based pharmaceutical company is engaged in the manufacture of active pharmaceutical ingredients and formulations with a focus on oncology. The company owns a retail pharmacy store chain in the US and a small distribution business in Brazil. It is also engaged in contract manufacturing. As part of its marketing strategy, Natco has tied up with leading companies such as Mylan, Dr Reddy''s Labs, Actavis, Breckinridge and Lupin.Net sales and net profit have grown at a CAGR of 20.6% and 17.5%, respectively, in the last five fiscals. The company has been paying dividends since the last five years at an average payout of 10.5%. It plans to spend nearly 5% of its revenues on R&D. The company recently raised Rs 67.5 crore through a qualified institutional placement to fund its expansion plans and meet its working capital requirements. A couple of private equity players have picked up a small stake in the company. Dilip Shanghvi, the promoter of Sun Pharma, has bought a 3.2% stake.Natco Pharma''s stock which had depreciated by 40% in the last 12 months to November, has gained by 20% after the stake deals. With a market capitalisation of Rs 692 crore, the company is valued at one-and-a-half times its consolidated revenues during the last four trailing quarters. These are fair valuations given that the stock is a long-term play for the investors.
Sunday, December 11, 2011
Suven Life Sciences Ltd:-Buy/sell/,growth prospects and recommendation,news and results,target price and analysis,view and outlook,multibagger
ScripScan:Suven Life Sciences Ltd
code:530239
Cmp:14
Story:Partnership business model with Innovator Drug Companies.Partnering development of under patent molecules.Partnering drug discovery and development of New Chemical Entities with global drug majors.Partnering with multinationals for contract manufacturing.Leveraging relationships with 25 global life science companies.Offering a clear value proposition to multinationals in cutting costs,time to market and outsourcing research capabilities.Successful transformation in supplying products from grams to tons.The company was very much in the limelight recently. The stock has recovered from its recent low of 15rs. The spike up in the stock was after the company announced that its has received four product patent approvals - three from Australia and one from New Zealand, which could be used for treating various central nervous disorders.These patents are valid through 2027. With these new patents, the company now has eleven patents from Australia and twelve from New Zealand. Financially, the company did not do well in Q1FY12. Though the company showed a rise in net income for the quarter at Rs.44.63 crore v/s Rs.35.92 crore in Q1FY11, its net profit showed a decline of 2.32% at Rs.3.36 crore. On an equity of Rs.11.67 crore, this Re.1 face value stock has an annualized EPS of Rs.1.16 and this discounts the current price by 13 times.One shouldnt expect huge returns till the company reports robust numbers.At present its a hold.
code:530239
Cmp:14
Story:Partnership business model with Innovator Drug Companies.Partnering development of under patent molecules.Partnering drug discovery and development of New Chemical Entities with global drug majors.Partnering with multinationals for contract manufacturing.Leveraging relationships with 25 global life science companies.Offering a clear value proposition to multinationals in cutting costs,time to market and outsourcing research capabilities.Successful transformation in supplying products from grams to tons.The company was very much in the limelight recently. The stock has recovered from its recent low of 15rs. The spike up in the stock was after the company announced that its has received four product patent approvals - three from Australia and one from New Zealand, which could be used for treating various central nervous disorders.These patents are valid through 2027. With these new patents, the company now has eleven patents from Australia and twelve from New Zealand. Financially, the company did not do well in Q1FY12. Though the company showed a rise in net income for the quarter at Rs.44.63 crore v/s Rs.35.92 crore in Q1FY11, its net profit showed a decline of 2.32% at Rs.3.36 crore. On an equity of Rs.11.67 crore, this Re.1 face value stock has an annualized EPS of Rs.1.16 and this discounts the current price by 13 times.One shouldnt expect huge returns till the company reports robust numbers.At present its a hold.
Fulford (India) Ltd:-Buy/sell/,growth prospects and recommendation,news and results,target price and analysis,view and outlook,multibagger
ScripScan:Fulford (India) Ltd
code:506803
Cmp:540
History:Fulford (India) Limited is an subsidiary of Schering-Plough Corporation, USA, a leading research-based company, engaged primarily in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.Fulford ( India) Limited was incorporated 1948. It was then registered under the name C. E. Fulford (India) Private Limited and was 100% owned by C. E. Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal ointments, marketed under the trademarks – PEPS and ZAMBUK respectively.On July 1, 1968, Schering-Corporation, USA, an international research-based pharmaceutical company acquired 100% ownership of C. E. Fulford Limited, UK. Subsequently, a manufacturing plant was set up at Andheri for the manufacture of pharmaceutical products. The company’s operations commenced with the introduction of an antibiotic injection under the brand name GARAMYCIN and an antifungal skin solution under the brand name TINADERM.In 1971, Schering Corporation merged with Plough Inc., a mass merchandiser of popular consumer products and Schering-Plough Corporation was formed. Schering-Plough has its headquarters and executive offices at New Jersey, USA.In August 1981, the company changed its status from a private company to a public company and from January 1, 1982 diluted the foreign shareholding from 100% to 40%, to fall in line with the prevailing Government policy.In 2006, the Company made a preferential allotment of 7,00,000 equity shares at a price of Rs. 575/- each (inclusive of a premium of Rs. 565/- each), to its promoter, Dashtag, U.K.
Story:Fulford is a leading India centric player in the dermatology segment of the pharmaceutical space with a strong brand franchise.It offers its products for various diseases and conditions, including allergy and respiratory, arthritis and immunology, cancer therapies, cardiovascular, hepatitis, sun care, skin disorders, and systemic anti infective diseases.De-risking the product portfolio away from dermatology is now working well after initial teething troubles.The stock at present quotes at 10-12 times its expected forward earnings.The stock has been steady performer over the last 5 years.Fulford is the most compelling MNC pharmaceutical company in terms of valuation.A safe bet altogether.
code:506803
Cmp:540
History:Fulford (India) Limited is an subsidiary of Schering-Plough Corporation, USA, a leading research-based company, engaged primarily in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.Fulford ( India) Limited was incorporated 1948. It was then registered under the name C. E. Fulford (India) Private Limited and was 100% owned by C. E. Fulford Limited of UK. Until 1968, the company was engaged in the business of manufacturing and marketing pharmaceutical consumer products, including cough tablets and herbal ointments, marketed under the trademarks – PEPS and ZAMBUK respectively.On July 1, 1968, Schering-Corporation, USA, an international research-based pharmaceutical company acquired 100% ownership of C. E. Fulford Limited, UK. Subsequently, a manufacturing plant was set up at Andheri for the manufacture of pharmaceutical products. The company’s operations commenced with the introduction of an antibiotic injection under the brand name GARAMYCIN and an antifungal skin solution under the brand name TINADERM.In 1971, Schering Corporation merged with Plough Inc., a mass merchandiser of popular consumer products and Schering-Plough Corporation was formed. Schering-Plough has its headquarters and executive offices at New Jersey, USA.In August 1981, the company changed its status from a private company to a public company and from January 1, 1982 diluted the foreign shareholding from 100% to 40%, to fall in line with the prevailing Government policy.In 2006, the Company made a preferential allotment of 7,00,000 equity shares at a price of Rs. 575/- each (inclusive of a premium of Rs. 565/- each), to its promoter, Dashtag, U.K.
Story:Fulford is a leading India centric player in the dermatology segment of the pharmaceutical space with a strong brand franchise.It offers its products for various diseases and conditions, including allergy and respiratory, arthritis and immunology, cancer therapies, cardiovascular, hepatitis, sun care, skin disorders, and systemic anti infective diseases.De-risking the product portfolio away from dermatology is now working well after initial teething troubles.The stock at present quotes at 10-12 times its expected forward earnings.The stock has been steady performer over the last 5 years.Fulford is the most compelling MNC pharmaceutical company in terms of valuation.A safe bet altogether.
Subscribe to:
Posts (Atom)